BI 456906 vs Cotadutide
Head-to-head comparison of BI 456906 (BI 456906, glucagon-like peptide-1/glucagon receptor dual agonist) and Cotadutide (MEDI0382, long-acting GLP-1 and glucagon receptor dual agonist) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | BI 456906 | Cotadutide |
|---|---|---|
| Category | Weight Management | Weight Management |
| Full Name | BI 456906, glucagon-like peptide-1/glucagon receptor dual agonist | MEDI0382, long-acting GLP-1 and glucagon receptor dual agonist |
| Molecular Weight | N/A | ~4,700 Da |
| Half-Life | Approximately 1 week | Approximately 24 hours |
| Amino Acids | N/A | 37 |
| Typical Dose | Trial-dependent; weekly SC dosing | 0.3-3 mg daily in clinical studies |
| Route | Subcutaneous | Subcutaneous |
| Purity | ≥98% | ≥98% |
| Studies Count | 10 | 18 |
| Research Status | Clinical | Clinical |
BI 456906 Benefits
- ✓weight reduction
- ✓improved glucose control
- ✓lower liver-fat burden
- ✓enhanced satiety
Cotadutide Benefits
- ✓body-weight reduction
- ✓improved insulin sensitivity
- ✓reduced hepatic fat
- ✓appetite suppression
BI 456906 Dosing
once-weekly subcutaneous injection|stepwise titration|ongoing maintenance phase
Cotadutide Dosing
Once-daily SC in trials|Start low and titrate based on tolerance|Monitor GI adverse effects
BI 456906 Side Effects
- ⚠nausea
- ⚠abdominal discomfort
- ⚠diarrhea
Cotadutide Side Effects
- ⚠nausea
- ⚠vomiting
- ⚠diarrhea
Research Overview
BI 456906
Preclinical and early clinical research support meaningful metabolic effects with a tolerable safety profile. It remains investigational and is not commercially available.
Cotadutide
Phase 2 studies reported dose-dependent weight loss and favorable changes in glycemic and liver-related markers. It is one of the most cited synthetic dual-agonist peptides for obesity research.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.